Grand Venture Technology embarks on the next chapter of global growth as Aalberts completes the privatisation of the company SINGAPORE,…
Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant weight loss, with one in three study participants…
Results from a real-world survey suggest that semaglutide for weight management (Wegovy®) helped suppress food noise – unwanted and intrusive…
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke…
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an…
LOS ANGELES--(BUSINESS WIRE)--$NVO--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against…
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for…
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of…
Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25%…
Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was…